CLINICAL EVALUATION OF CEFTERAM PIVOXIL IN THE PEDIATRIC FIELD

Cefteram pivoxil (CFTM-PI, T-2588), a new oral cephalosporin antibiotic, was evaluated for its safety and efficacy in children. Fifty-three patients with bacterial infections were treated with 8.3 to 21.8 mg/kg/day of CFTM-PI. The drug was very effective (efficacy rate 98.1%) in pharyngitis, otitis...

Full description

Saved in:
Bibliographic Details
Published in:Japanese journal of antibiotics 1989/08/25, Vol.42(8), pp.1815-1827
Main Authors: MEGURO, HIDENORI, ARIMASU, OSAMU, TAJIMA, TAKESHI, SHIRAISHI, HIROAKI, KOBAYASHI, MASAAKI, ABE, TOSHIAKI
Format: Article
Language:Japanese
Subjects:
Adolescent
Bacterial Infections - drug therapy
Cefmenoxime - adverse effects
Cefmenoxime - analogs & derivatives
Cefmenoxime - pharmacology
Cefmenoxime - therapeutic use
Child
Child, Preschool
Drug Evaluation
Female
Humans
Infant
Male
Microbial Sensitivity Tests
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cefteram pivoxil (CFTM-PI, T-2588), a new oral cephalosporin antibiotic, was evaluated for its safety and efficacy in children. Fifty-three patients with bacterial infections were treated with 8.3 to 21.8 mg/kg/day of CFTM-PI. The drug was very effective (efficacy rate 98.1%) in pharyngitis, otitis media, tracheobronchitis, pneumonia and skin infections. The antibacterial potency was very good against Haemophilus influenzae, Streptococcus pyogenes and Streptococcus pneumoniae, and was comparable with cephalexin against Staphylococcus aureus. No severe adverse reaction was encountered with the CFTM-PI therapy. The data suggest that CFTM-PI is a safe and effective antibiotic when used in children with susceptible bacterial infections.
ISSN:0368-2781
2186-5477
DOI:10.11553/antibiotics1968b.42.1815